LAVAL, QC, Nov. 10 /PRNewswire-FirstCall/ - LAB International Inc. (“LAB”), an integrated drug development company focused on developing therapies for the inhalation market, today announced that it will report financial results for the third quarter of fiscal 2006 ended September 30, 2006 on Tuesday November 14, 2006.
LAB will host a conference call at 10:00 a.m., on Tuesday November 14, 2006. Interested parties may also access the conference call by webcast at www.labinc.ca.
The telephone number to access the conference call is 1-800-814-3911. A replay of the call will be available until November 21, 2006. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21209669(pound key).
About LAB International
LAB International is an integrated drug development company focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company’s TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies.
LAB’s common shares trade on The Toronto Stock Exchange (“TSX”) under the symbol “LAB”, on the Frankfurt Regulated Unofficial Market under the symbol “LD9.F” and on XETRA under the symbol “LD9.DE” with 74.5 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB International Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
LAB INTERNATIONAL INC.
CONTACT: visit LAB’s website at www.labinc.ca, or contact: FredericDumais, Vice-President, Investor Relations, (514) 315-3330 ext. 106, Fax:(514) 315-3325, dumaisf@labinc.ca
